N/A
N=101
Improving Medication Adherence in Older African Americans With Diabetes
Type 2 Diabetes · Mild Cognitive Impairment
Bottom Line
View on ClinicalTrials.gov: NCT02174562 ↗Enrolled (actual)
101
Serious AEs
33.7%
Results posted
Jun 2020
Primary outcome: Primary: Percent of Participants With Improvement in Hemoglobin A1c by 0.5%" — 25; 22 Participants — p=0.31
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Primary Care-Occupational Therapy (Behavioral); Enhanced Usual Care (Behavioral)
- Age
- Adult, Older Adult · 60+ yrs
- Sex
- All
- Sponsor
- Thomas Jefferson University
- Primary completion
- Dec 2019
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Percent of Participants With Improvement in Hemoglobin A1c by 0.5%" |
25; 22 | 0.31 |
| SECONDARY Adherence as Measured By Percentage of Doses Taken as Prescribed |
61; 60 | 0.87 |
Summary
This research aims to help older African Americans with diabetes and mild memory problems improve how they take their medications and control their diabetes. This may preserve their independence and health, prevent cognitive and functional decline, and reduce health care costs. As the population ages and becomes more racially diverse, finding ways to achieve these outcomes has great public health importance.
Eligibility Criteria
Inclusion Criteria
- Age 60 years and older.
- Self-identified as African American, black, black American, or black/Caribbean.
- Type II DM (i.e., physician diagnosis and medication treatment).
- HbA1c level ≥ 7.5%.
- MCI, based on National Institute on Aging/Alzheimer's Association (NIA/AA) criteria.
- ≤ 80% adherence to an oral hypoglycemic medication or insuling, as documented during a run-in phase using a Medication Event Monitoring System (MEMS).
Exclusion Criteria
- Dementia, based on National Institute on Aging/Alzheimer's Association criteria.
- DSM-V psychiatric disorder other than depressive disorders.
- End-stage renal disease requiring dialysis.
- Hearing/Vision (i.e., severe diabetic retinopathy) or motor (e.g., peripheral neuropathy) impairment that precludes research participation.
Data sourced from ClinicalTrials.gov (NCT02174562). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.